Document text
Principal Investigator: Clifton Barry
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $1,276,926
Funding agency: National Institute of Allergy and Infectious Diseases
(1) NIAID 15-I-N070: Radiologic and immunologic biomarkers to enhance early bactericidal activity (EBA) measurements of sterilizing drug activity in tuberculosis (NexGen EBA). This study hypothesized that drug regimens associated with higher sterilizing activity show distinct cytokine patterns and quantifiable PET/CT changes in certain lesions during the EBA period, compared to those with lesser sterilizing activity. The primary objective was to characterize, in the context of a standard EBA study, the effect of various anti-TB drugs on radiographic and immunologic markers in treatment-naive subjects with pulmonary drug sensitive TB. The study was a collaboration with the Gates Foundation (BMGF) and was conducted in South Africa from 2015-2017. The primary analyses of microbiology, PET/CT, and biomarkers data are complete and a manuscript published. Secondary analyses are ongoing. PET/CT data on new drugs and combinations is being collected through the EDCTP funded CLICK-TB consortium.
(2) NIAID 16-I-N133: Using Biomarkers to Predict TB Treatment Duration. This study hypothesizes that a combination of radiographic characteristics at baseline, the rate of change of these features at one month, and markers of residual bacterial load at the end of treatment will identify TB patients who are cured with 4 months of standard treatment. The primary objective is to demonstrate that the month 18 treatment success rate of standard treatment stopped early at month 4 is not inferior to standard treatment stopped at month 6, in participants classified as lower risk for disease failure and relapse by radiographic and bacterial load markers. This is a collaboration funded by BMGF, the European and Developing Countries Clinical Trials Partnership (EDCTP), the National Natural Science Foundation of China, the China Ministry of Science and Technology, and NIH. Study enrollment began in 2017 in Western Cape, South Africa and Henan Province, China and enrolled about 310 participants into the two lower risk arms. The study is expected to conclude in FY 2023. One manuscript was published last year. Study enrollment was slowed and follow-up has been made more complicated by the COVID-19 pandemic.
(3) anTBiotic consortium: This is a consortium led by GSK and includes University of Tromso, Research Center Borstel, University of Cape Town, TASK Applied Science in Cape Town to develop and advance novel anti-TB clinical drug candidates, including a novel GSK compound, meropenem, and other B-lactam antibiotics against MDR-TB. Single drugs and drug combinations are explored in 2-week NexGen EBA studies, along with biomarker-guided treatment durations that will be evaluated in future trials. The study is being conducted at TASK. The clinical phase of this study has concluded and the data are now being analyzed. This study is primarily funded by EDCTP. Data analyses have been slowed by the COVID-19 pandemic.
(4) Novel Clinical Candidates to Kill TB (Click-TB) consortium: This is a consortium led by GSK and includes Research Center Borstel, University of Cape Town, TASK Applied Science in Cape Town. The aim is to identify a universal treatment regimen for TB that is ready to move into a phase 2b or 3 clinical trial. Three novel compounds and recently approved drugs will be included. Two-week NexGen EBA studies are being conducted on 2-drug combinations followed by 4-week trials of 3- or 4-drug combinations. The best 3- or 4-drug combinations will be ready for a future phase 2b or 3 clinical trial. The clinical trial is currently ongoing, conducted by TASK. This study is primarily funded by EDCTP. The conduct of the trial and data analyses have been slowed by the COVID-19 pandemic.
(5) DMID Protocol Number 13-0029: Award# N01AI90500C: Feasibility and accuracy of a novel Xpert cartridge for rapid molecular detection of drug resistant Mycobacterium tuberculosis in sputum. This prospective, cross-sectional study was conducted with the Clinical Diagnostics Research Consortium (PI: Susan Dorman, Medical University of South Carolina) in China and South Korea and is now completed. The investigational Xpert XDR cartridge accurately detected Mtb mutations associated with resistance to isoniazid, fluoroquinolones, and aminoglycosides; primary results were published in the New England Journal of Medicine. Samples from this study will be used to develop newer Xpert cartridges.
Terms: <Active Follow-up><Aminoglycosides><Antitubercular Agents><Antitubercular Drugs><Applied Research><Applied Science><Area><Award><Biological Markers><COVID complications><COVID crisis><COVID epidemic><COVID pandemic><COVID related complications><COVID-19 complications><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 related complications><COVID-19 years><CXR><Cause of Death><Characteristics><China><Chinese><Classification><Clinical><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Conduct Clinical Trials><Cross Sectional Analysis><Cross-Sectional Analyses><Cross-Sectional Studies><Cross-Sectional Survey><Data><Data Analyses><Data Analysis><Developing Countries><Developing Nations><Diagnostic tests><Diagnostics Research><Disease><Disease Frequency Surveys><Disorder><Drug Combinations><Drug resistance><Drug resistance in Mtb><Drug resistance in Mycobacterium Tuberculosis><Drug resistant M Tuberculosis><Drug resistant Mtb><Drug resistant Mycobacteria Tuberculosis><Drugs><Enrollment><European><Extreme drug resistant tuberculosis><Extremely drug resistant tuberculosis><Failure><Fluoroquinolones><Foundations><Funding><Future><General Radiology><Genetic Alteration><Genetic Change><Genetic defect><Goals><INH resistance><INH resistant><Immune Markers><Immunologic Markers><Infectious Agent><International><Intervention><Intervention Strategies><Investigators><Isoniazid resistance><Isoniazid resistant><Journals><Lactam Antibiotics><Lesion><Less-Developed Countries><Less-Developed Nations><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lung><Lung Respiratory System><M tb><M tuberculosis><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MDR Tuberculosis><MDR-TB><MTB infection><Magazine><Mainland China><Manuscripts><Measurement><Medical><Medication><Medicine><Meropenem><Methodology><Methods><Microbiology><Molecular><Monobactam Antibiotics><Monobactams><Monocyclic beta-Lactams><Mtb drug resistance><Multi-Drug Resistant Tuberculosis><MultiDrug Resistance Tuberculosis><Multidrug-Resistant Tuberculosis><Mutation><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Natural Sciences><New England><Northeastern United States><PET/CT><PET/CT scan><Participant><Patients><Pattern><Pharmaceutical Preparations><Phase><Protocol><Protocols documentation><Province><Public Health><Publishing><Radiography><Radiology><Radiology Specialty><Regimen><Relapse><Reporting><Republic of Korea><Research><Research Personnel><Research Resources><Researchers><Residual><Residual state><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Resources><Risk><Roentgenography><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Sampling><Sampling Studies><Science><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><South Africa><South African><South Carolina><South Korea><Sputum><Systematics><TB chemotherapy><TB diagnosis><TB drugs><TB infection><TB therapy><TB treatment><Technology><Testing><Third-World Countries><Third-World Nations><Thoracic Radiography><Translational Research><Translational Science><Treatment Period><Treatment Protocols><Treatment Regimen><Treatment Schedule><Tuberculosis><Tuberculosis diagnosis><Tuberculostatic Agents><Under-Developed Countries><Under-Developed Nations><United States National Institutes of Health><Universities><XDR-TB><XDR-Tuberculosis><active followup><anti-TB><anti-TB drugs><anti-tuberculosis><anti-tuberculosis drugs><antiTB><arm><bactericidal><bactericide><bio-markers><biologic marker><biomarker><chest X ray><chest Xray><chest radiography><clinical candidate><clinical development><clinical diagnostics><complications due to COVID-19><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><cytokine><data interpretation><developing country><developing nation><diagnosed with TB><diagnosed with Tuberculosis><disease diagnosis><disease risk><disorder risk><disseminated TB><disseminated tuberculosis><drug adherence><drug candidate><drug compliance><drug detection><drug resistance M Tuberculosis><drug resistance Mycobacteria Tuberculosis><drug resistant><drug resistant M.tb><drug testing><drug-sensitive><drug/agent><effective therapy><effective treatment><enroll><extensively drug resistant TB><extensively drug resistant tuberculosis><follow up><follow-up><followed up><followup><genome mutation><immune-based biomarkers><immunological biomarkers><immunological markers><improved><infection due to Mycobacterium tuberculosis><infectious organism><interventional strategy><lung radiography><medical diagnostic><medication adherence><medication compliance><mtb><multidrug-resistant TB><new diagnostics><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation diagnostics><next generation therapeutics><novel><novel diagnostics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><positron emission computed tomography><prospective><pulmonary><radiographic chest image><radiographic lung image><radiologic imaging><radiological imaging><rate of change><resistance to Drug><resistance to isoniazid><resistant to Drug><resistant to isoniazid><response to therapy><response to treatment><secondary analysis><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><standard care><standard treatment><success><therapeutic response><therapy response><thoracic radiogram><thorax radiography><translation research><translational investigation><treat M. tuberculosis><treat Mtb><treat Mycobacterium tuberculosis><treat tb><treat tuberculosis><treatment days><treatment duration><treatment response><treatment responsiveness><treatment strategy><tuberculosis chemotherapy><tuberculosis drugs><tuberculosis infection><tuberculosis therapy><tuberculosis treatment><tuberculous spondyloarthropathy><week trial>